Italia markets closed

Arrowhead Pharmaceuticals, Inc. (0HI3.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
33,77+0,98 (+2,99%)
Alla chiusura: 03:14PM GMT
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones

    Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement NEW YORK and PASADENA, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Arrowhead today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals (Nasd